Hormone therapy

The female reproductive organs, including the external parts such as the vagina, the pelvic floor, the bladder and the lower urinary tract are hormone-dependent structures. Patients with a hormone deficiency, especially an oestrogen deficiency, are more susceptible to inflammation in the urinary and genital tract. Hormone deficiencies may also lead to slackening in the bladder and urethra. This, in turn, frequently causes incontinence (involuntary leakage of urine). This is why we often recommend that at the start of any incontinence treatment patients undergo local (i.e. via the vagina) hormone therapy to treat the structures which contribute to the development of incontinence.

The hormones can be administered in the form of a vaginal suppository, vaginal cream or tablet inserted into the vagina. The method of application and dose is tailored to the individual patient and agreed on with their registered gynaecologist.

Oestriol, a female sex hormone, is used as a purely local treatment. In complete contrast to oestradiol, it has no effect on the uterus and bones. Although it does not generally cause any vaginal bleeding, it does not provide any protection against osteoporosis (weakening of the bones) and does not have a positive impact on lipid metabolism either.

Oestriol improves circulation and tissue structure in the lower genitals (urethra, bladder and vagina) and contributes to a normal vaginal environment. It is therefore an essential part of the conservative treatment of urinary incontinence, is vital for preventing ulcers during pessary treatment and is a very important pre-treatment before incontinence or prolapse surgery. It also reduces the frequency of urge incontinence symptoms, vulvovaginal symptoms (itching, vaginal dryness), urinary tract infections and dyspareunia (pain during intercourse).
Hormone therapy is suitable for treating stress incontinence, urge incontinence and mixed incontinence.